<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
CLSD
Clearside Biomedical
$
()


  • Clearside Biomedical appoints Chong as Chief Medical Officer

    3/18/2024 - 07:07am
  • Clearside to sell 11.11M shares at $1.35 in registered direct offering

    2/7/2024 - 08:17am
  • Clearside Biomedical reports progress in ODYSSEY Phase 2b trial of CLS-AX

    12/14/2023 - 07:08am
  • Clearside Biomedical reports Q3 EPS (15c), consensus (15c)

    11/13/2023 - 16:32pm
  • Clearside to receive $5M upfront in license agreement with BioCryst

    11/3/2023 - 12:04pm
  • Clearside Biomedical completes recruitment in ODYSSEY Phase 2b trial

    11/1/2023 - 07:42am
  • Clearside Biomedical presented key data from Phase 1/2a OASIS trial

    10/16/2023 - 07:21am
  • Clearside Biomedical announces advancement of XIPERE in Asia-Pacific

    10/4/2023 - 09:05am
  • Clearside Biomedical reports Q2 EPS (15c), consensus (14c)

    8/14/2023 - 16:26pm
  • Clearside Biomedical presents safety, tolerability data from OASIS trial

    7/31/2023 - 07:23am
  • Clearside's Suprachoroidal Injection platform to be featured at ASRS, OIS

    7/20/2023 - 07:11am
  • Clearside Biomedical announces enrollment, dosing of participants in ODYSSEY

    7/17/2023 - 07:15am
  • Clearside announces TGA of Australia accepted Arctic Vision's NDA for Arcatus

    7/10/2023 - 07:09am
  • Clearside Biomedical initiated with a Buy at JonesResearch

    6/14/2023 - 06:09am
  • Clearside Biomedical opens enrollment in ODYSSEY Phase 2b trial of CLS-AX

    6/1/2023 - 07:12am
dynamic_feed Breaking News